Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
Anas Younes, SVP, CMO and Global Head of Hematology, Oncology R and D at AstraZeneca, shared on LinkedIn:
”Every year, ASH25 is a moment to recognize the progress we’re making in hematology and celebrate the breakthroughs that help to transform care, from next-generation T-cell engagers to advances in cell therapy.
At AstraZeneca, we’re advancing a diverse range of innovations and expanding access to next-generation therapies that aim to deliver deeper, more durable responses while easing the daily burden of treatment for people living with blood cancer.
It’s great to continue these conversations throughout ASH and explore how these breakthroughs are potentially shaping a more hopeful future for blood cancer care.
Read my latest article to learn more.”
All from ASH25 featured in Hemostasis Today.
-
Jul 31, 2026, 04:35Lukas Bastian Otto: Bow Hunter’s Syndrome as a Hidden Cause of Cerebellar Infarction
-
Jul 31, 2026, 04:05Shadi Tabibian: Understanding Thrombotic Risk in Rare Bleeding Disorders
-
Jul 31, 2026, 03:43American Society of Hematology Opens Doors to Hematology Education Worldwide
-
Jul 31, 2026, 03:23Roberta Gualtierotti: Major Genomic Study Identifies Novel Fibromyalgia Risk Genes
-
Jul 30, 2026, 18:36Amina Ammar: Evaluating Rivaroxaban Dosing Alignment Across Cockcroft–Gault and eGFR Equations
-
Jul 30, 2026, 18:11Tobias Tritschler: Evaluating Timing, Translation and Preparedness in COVID-19 Anticoagulation Management
-
Jul 30, 2026, 16:05Peter Zdziarski: Today is Chronic Disease Awareness Day
-
Jul 30, 2026, 15:50Ahmad Gharehbaghian: New Blood Transfusion Centers Open in Iran
-
Jul 30, 2026, 15:32Can We Better Protect Hospitalized Patients With Obesity From Venous Thromboembolism? – RPTH Journal